{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-040826","form_type":"8-K","ticker":"NRXS","cik":"0001933567","company_name":"Neuraxis, INC","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.420058+00:00","generated_at":"2026-06-08T04:10:26.356714+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Neuraxis secures $3M financing via Series B preferred stock at $2.38/share","bullets":["Aggregate purchase price $3,000,000; paid in 15 monthly installments of $200,000 each.","Transaction subject to stockholder approval of Series B Preferred Stock amendment.","Series B convertible into common stock; ranks senior to common on liquidation.","Funds to support sales/marketing for IB-Stim™ and launch of RED device in 2024.","Investor is Flagstaff International, an affiliate of Inspire Health Alliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-040826","json":"https://secwatch.observer/filing/0001493152-23-040826.json","markdown":"https://secwatch.observer/filing/0001493152-23-040826.md","text":"https://secwatch.observer/filing/0001493152-23-040826.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1933567/000149315223040826/0001493152-23-040826-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1933567/000149315223040826/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:10:26.356714+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c5766f6b5d60f6901da987bc571832a8dd1c99e5","claim":"Neuraxis, INC entered into SPA with Flagstaff International, LLC valued at $3,000,000 (effective 2023-11-09).","evidence_excerpt":"On November 9, 2023, Neuraxis, Inc. (the “Company”) entered into a securities purchase agreement (the “SPA”) with Flagstaff International, LLC ( “Flagstaff International”) for the issuance and purchase of the Company’s Series B Convertible Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”), at price per share of $2.38. The aggregate purchase price is $3,000,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1933567/000149315223040826/0001493152-23-040826-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Flagstaff International, LLC"},{"label":"Value","value":"$3,000,000"},{"label":"Effective","value":"2023-11-09"}],"fact_type":"material_agreement"},{"claim_id":"f53397c71b11974d0c9dc111c1a4570d1c4708c1","claim":"Neuraxis, INC entered into Registration Rights Agreement with Flagstaff International (effective 2023-11-09).","evidence_excerpt":"In connection with the SPA, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Flagstaff International.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1933567/000149315223040826/0001493152-23-040826-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Flagstaff International"},{"label":"Effective","value":"2023-11-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}